GB1498903A
(en)
*
|
1974-03-25 |
1978-01-25 |
Fabre Sa Pierre |
Aromatic keto-acids and their derivatives
|
US4231938A
(en)
*
|
1979-06-15 |
1980-11-04 |
Merck & Co., Inc. |
Hypocholesteremic fermentation products and process of preparation
|
US4444784A
(en)
*
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
MX7065E
(es)
*
|
1980-06-06 |
1987-04-10 |
Sankyo Co |
Un procedimiento microbiologico para preparar derivados de ml-236b
|
US5366738A
(en)
*
|
1982-07-29 |
1994-11-22 |
Merck & Co., Inc. |
Controlled release drug dispersion delivery device
|
US4739073A
(en)
*
|
1983-11-04 |
1988-04-19 |
Sandoz Pharmaceuticals Corp. |
Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
|
US4882167A
(en)
*
|
1983-05-31 |
1989-11-21 |
Jang Choong Gook |
Dry direct compression compositions for controlled release dosage forms
|
US4590062A
(en)
*
|
1984-04-16 |
1986-05-20 |
Tech Trade Corp. |
Dry direct compression compositions for controlled release dosage forms
|
US4629620A
(en)
*
|
1984-09-05 |
1986-12-16 |
Ab Ferrosan |
Membrane-coated sustained-release tablets and method
|
US4920098A
(en)
*
|
1986-09-17 |
1990-04-24 |
Baxter International Inc. |
Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
|
FI94339C
(fi)
*
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US5157022A
(en)
*
|
1989-11-22 |
1992-10-20 |
Adrian Barbul |
Method for reducing blood cholesterol using arginine
|
US5576351A
(en)
*
|
1989-12-29 |
1996-11-19 |
Mcgaw, Inc. |
Use of arginine as an immunostimulator
|
EP0441119A3
(en)
*
|
1990-01-09 |
1992-10-14 |
Richard D. Levere |
The use of l-arginine in the treatment of hypertension and other vascular disorders
|
US5395612A
(en)
*
|
1990-03-27 |
1995-03-07 |
Cornell Research Foundation, Inc. |
Method for treating systemic hypotension caused by sepsis or cytokine using arginase in combination with an α1 adrenergic agonist
|
US5300288A
(en)
*
|
1991-04-05 |
1994-04-05 |
Rohm And Haas Company |
Composition and method for controlling cholesterol
|
US5145684A
(en)
*
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
US5543154A
(en)
*
|
1991-12-27 |
1996-08-06 |
Merck & Co., Inc. |
Controlled release nifedipine delivery device
|
US6187744B1
(en)
*
|
1992-03-11 |
2001-02-13 |
Michael W. Rooney |
Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
|
NZ247617A
(en)
*
|
1992-05-15 |
1995-07-26 |
Sankyo Co |
Octahydronaphthalene oxime derivatives and pharmaceutical compositions
|
US5470845A
(en)
*
|
1992-10-28 |
1995-11-28 |
Bristol-Myers Squibb Company |
Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
|
US5385940A
(en)
*
|
1992-11-05 |
1995-01-31 |
The General Hospital Corporation |
Treatment of stroke with nitric-oxide releasing compounds
|
US5326569A
(en)
*
|
1992-12-23 |
1994-07-05 |
Abbott Laboratories |
Medical foods for the nutritional support of child/adult metabolic diseases
|
US5891459A
(en)
*
|
1993-06-11 |
1999-04-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
|
US5945452A
(en)
*
|
1993-06-11 |
1999-08-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
|
US5861168A
(en)
*
|
1993-06-11 |
1999-01-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
|
US5428070A
(en)
*
|
1993-06-11 |
1995-06-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
|
US5595970A
(en)
*
|
1993-07-16 |
1997-01-21 |
Schering Aktiengesellschaft |
Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
|
US5895783A
(en)
*
|
1993-07-16 |
1999-04-20 |
Schering Aktiengesellschaft |
Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
|
US5952296A
(en)
*
|
1993-07-27 |
1999-09-14 |
Bigazzi; Mario |
Method of using relaxin as therapeutic or preventing agent
|
US5631373A
(en)
*
|
1993-11-05 |
1997-05-20 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon |
Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
|
US5470847A
(en)
*
|
1993-12-10 |
1995-11-28 |
Board Of Regents, The University Of Texas System |
Ovulation control by regulating nitric oxide levels with arginine derivatives
|
US5441946A
(en)
*
|
1994-04-14 |
1995-08-15 |
Rhone-Poulenc-Rorer Pharmaceuticals, Inc. |
Phosphonate derivatives of lipophilic amines
|
US5811416A
(en)
*
|
1994-06-06 |
1998-09-22 |
Board Of Regents The University Of Texas System |
Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
|
US6239172B1
(en)
*
|
1997-04-10 |
2001-05-29 |
Nitrosystems, Inc. |
Formulations for treating disease and methods of using same
|
US5543430A
(en)
*
|
1994-10-05 |
1996-08-06 |
Kaesemeyer; W. H. |
Method and formulation of stimulating nitric oxide synthesis
|
US6425881B1
(en)
*
|
1994-10-05 |
2002-07-30 |
Nitrosystems, Inc. |
Therapeutic mixture useful in inhibiting lesion formation after vascular injury
|
US5968983A
(en)
*
|
1994-10-05 |
1999-10-19 |
Nitrosystems, Inc |
Method and formulation for treating vascular disease
|
US5648101A
(en)
*
|
1994-11-14 |
1997-07-15 |
Tawashi; Rashad |
Drug delivery of nitric oxide
|
US5681819A
(en)
*
|
1994-12-01 |
1997-10-28 |
Oklahoma Medical Research Foundation |
Method and compositions for reducing cholesterol absorption
|
JP3598389B2
(ja)
*
|
1995-01-24 |
2004-12-08 |
大塚製薬株式会社 |
粉末清涼飲料製剤の安定保存法及び粉末清涼飲料製剤
|
US5900433A
(en)
*
|
1995-06-23 |
1999-05-04 |
Cormedics Corp. |
Vascular treatment method and apparatus
|
IT1277898B1
(it)
*
|
1995-08-03 |
1997-11-12 |
Mendes Srl |
Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
|
EP0765660A3
(en)
*
|
1995-09-28 |
1998-09-23 |
Takeda Chemical Industries, Ltd. |
Microcapsules comprising 2-piperazinone-1-acetic acid compounds
|
SE9600070D0
(sv)
*
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US5789442A
(en)
*
|
1996-01-18 |
1998-08-04 |
Schering Aktiengesellschaft |
Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
|
US5895788A
(en)
*
|
1996-01-31 |
1999-04-20 |
The Board Of Trustees Of The University Of Arkansas |
Use of L-arginine and salts thereof in drinking water for the prevention and/or treatment of pulmonary hypertension syndrome in avians
|
US6127421A
(en)
*
|
1996-01-31 |
2000-10-03 |
The Board Of Trustees Of The University Of Arkansas |
In ovo use of L-arginine and salts thereof in the prevention and/or treatment of pulmonary hypertension syndrome in avians
|
US6323211B1
(en)
*
|
1996-02-02 |
2001-11-27 |
Nitromed, Inc. |
Compositions and methods for treating sexual dysfunctions
|
US5898038A
(en)
*
|
1996-03-19 |
1999-04-27 |
Board Of Regents, The University Of Texas System |
Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
|
US5910482A
(en)
*
|
1996-03-19 |
1999-06-08 |
Board Of Regents, The University Of Texas System |
Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
|
US6040340A
(en)
*
|
1996-05-07 |
2000-03-21 |
Schering Aktiengesellschaft |
Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
|
US5789422A
(en)
*
|
1996-10-28 |
1998-08-04 |
Schering Corporation |
Substituted arylalkylamines as neurokinin antagonists
|
US6210700B1
(en)
*
|
1997-01-14 |
2001-04-03 |
Novartis Nutrition Ag |
Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
|
US5788987A
(en)
*
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
US5912019A
(en)
*
|
1997-02-07 |
1999-06-15 |
Musc Foundation For Research Development |
Compounds for reducing ischemia/reperfusion injury
|
US6028107A
(en)
*
|
1997-02-27 |
2000-02-22 |
Waugh; William Howard |
Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
|
US5906987A
(en)
*
|
1997-03-10 |
1999-05-25 |
Schering Aktiengesellschaft And Board Of Regents |
Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
|
US6312724B1
(en)
*
|
1997-04-04 |
2001-11-06 |
Isa Odidi |
Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
|
US20030114515A1
(en)
*
|
1997-04-10 |
2003-06-19 |
Kaesemeyer Wayne H. |
Therapeutic mixture of HMG-COA reductase inhibitors
|
US6207713B1
(en)
*
|
1997-09-17 |
2001-03-27 |
Eric T. Fossel |
Topical and oral delivery of arginine to cause beneficial effects
|
US5922332A
(en)
*
|
1997-09-17 |
1999-07-13 |
Fossel; Eric T. |
Topical delivery of arginine to overcome pain
|
US5895658A
(en)
*
|
1997-09-17 |
1999-04-20 |
Fossel; Eric T. |
Topical delivery of L-arginine to cause tissue warming
|
US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
US20050038102A1
(en)
*
|
1997-10-14 |
2005-02-17 |
Brigham And Womens Hospital |
Upregulation of type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
JP2001519386A
(ja)
*
|
1997-10-15 |
2001-10-23 |
トーマス・ジェファーソン・ユニバーシティ |
哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
|
PL193086B1
(pl)
*
|
1997-10-27 |
2007-01-31 |
Reddys Lab Ltd Dr |
Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie
|
US6174548B1
(en)
*
|
1998-08-28 |
2001-01-16 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
US6558699B2
(en)
*
|
1997-11-17 |
2003-05-06 |
Smithkline Beecham Corporation |
High drug load immediate and modified release oral dosage formulations and processes for their manufacture
|
WO1999026657A1
(en)
*
|
1997-11-25 |
1999-06-03 |
Musc Foundation For Research Development |
Inhibitors of nitric oxide synthase
|
AU1770299A
(en)
*
|
1997-12-23 |
1999-07-19 |
Nycomed Imaging As |
Nitric oxide releasing chelating agents and their therapeutic use
|
US6180597B1
(en)
*
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
US6063432A
(en)
*
|
1998-05-19 |
2000-05-16 |
Cooke Pharma |
Arginine or lysine containing fruit healthbar formulation
|
US6117872A
(en)
*
|
1998-06-23 |
2000-09-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
|
US6423751B1
(en)
*
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
US6207190B1
(en)
*
|
1998-08-13 |
2001-03-27 |
Chronorx, Llc |
Dosage forms for the treatment of the chronic glaucomas
|
JP2002539257A
(ja)
*
|
1999-03-19 |
2002-11-19 |
イーノス・ファーマシューティカルス・インコーポレーテッド |
薬剤の脳内生物学的利用率の増加
|
US6359007B1
(en)
*
|
1999-04-07 |
2002-03-19 |
Chronorx, Llc |
Clinical uses for L-arginine ascorbate and various metalloarginate complexes
|
US6419954B1
(en)
*
|
2000-05-19 |
2002-07-16 |
Yamanouchi Pharmaceutical Co., Ltd. |
Tablets and methods for modified release of hydrophilic and other active agents
|
US6475530B1
(en)
*
|
2000-05-31 |
2002-11-05 |
Eric H. Kuhrts |
Methods and compositions for producing weight loss
|
CA2412326A1
(en)
*
|
2000-06-09 |
2001-12-13 |
Lek Pharmaceuticals D.D. |
Stabilized hmg-coa reductase inhibitor pharmaceutical compositions
|
UA77660C2
(en)
*
|
2000-10-03 |
2007-01-15 |
|
Compositions and methods for reducing plasma lipoprotein a level in human
|
US6696094B2
(en)
*
|
2000-10-18 |
2004-02-24 |
Tzu-Sheng Wu |
Herbal pharmaceutical composition for treatment of HIV/AIDS patients
|
US6689385B2
(en)
*
|
2000-11-03 |
2004-02-10 |
Chronorx Llc |
Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
|
US6693094B2
(en)
*
|
2001-03-22 |
2004-02-17 |
Chrono Rx Llc |
Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
|
US20060029668A1
(en)
*
|
2002-10-24 |
2006-02-09 |
Ron Eyal S |
Sustained release L-arginine formulations and methods of manufacture and use
|
US20040208893A1
(en)
*
|
2002-12-16 |
2004-10-21 |
Daniels Bruce Alan |
Seaweed extract composition for treatment of diabetes and diabetic complications
|
US6797705B2
(en)
*
|
2002-12-16 |
2004-09-28 |
Endomatrix, Inc. |
Rhamnan sulphate composition for treatment of endothelial dysfunction
|
US20040180077A1
(en)
*
|
2003-03-05 |
2004-09-16 |
Riker Donald K. |
Rapidly dissolving edible strips for treating obesity
|